Stiff person syndrome (SPS) is not curable. No treatment can eliminate the underlying autoimmune process that drives the disease. However, a combination of symptom-management medications and immune-targeting therapies can significantly reduce stiffness, spasms, and disability for many people. In rare cases, aggressive immune treatments have produced sustained remissions lasting years.
What Happens in the Body
SPS is an autoimmune condition where the immune system produces antibodies that attack an enzyme responsible for making GABA, the brain’s primary calming chemical. GABA normally keeps nerve signals in check, preventing muscles from firing when they shouldn’t. When GABA production drops, neurons become hyperexcitable, and muscles stiffen and spasm without any voluntary command.
This process doesn’t cause visible structural damage to the brain or spinal cord, which is part of why SPS is so difficult to diagnose. The problem is functional: the chemical signaling between nerves is disrupted. Animal studies confirm this. When antibodies from SPS patients are transferred into rats, the animals develop continuous involuntary muscle activity and heightened spinal cord excitability.
How SPS Progresses Over Time
SPS typically starts slowly, with stiffness in the trunk and lower back that gradually spreads to the arms and legs. Over months to years, the rigidity worsens. Spasms can become severe enough to cause falls, fractures, and joint deformities. Without treatment, the disease can lead to permanent disability and, in some cases, death from complications like respiratory muscle involvement or injury from sudden falls.
Even with treatment, progression is common. In one long-term study, only 19% of patients were still able to work after four years. Some develop permanent skeletal changes from chronic muscle tension, and many eventually lose the ability to walk independently. That said, individual trajectories vary widely. Some people remain relatively stable for years on the right medication combination, while others decline despite aggressive treatment.
Why Everyday Life Becomes Difficult
One of the most disabling features of SPS is that ordinary stimuli can trigger intense muscle spasms. Sudden noises, unexpected touch, and emotional stress all act as triggers because the nervous system has lost its ability to dampen incoming signals. A car horn, a tap on the shoulder, or a moment of anxiety can set off painful, whole-body spasms that last seconds to minutes. Many people with SPS develop a fear of leaving the house, not from anxiety alone, but because the outside world is full of unpredictable triggers that cause real physical episodes and dangerous falls.
First-Line Treatments for Symptom Control
The primary goal of treatment is reducing muscle stiffness and spasm frequency enough that a person can function day to day. Benzodiazepines (most commonly diazepam) are the standard first-line treatment. They work by enhancing whatever GABA activity remains in the nervous system. Most patients respond well, though the doses required are often much higher than those used for anxiety, sometimes up to 60 mg of diazepam daily. This means side effects like sedation and dependence are real concerns.
If benzodiazepines alone aren’t enough, doctors typically add medications that further calm nerve excitability, such as pregabalin or levetiracetam. Baclofen, a muscle relaxant that acts on GABA receptors in the spinal cord, is another option when initial treatments fall short. These medications don’t address the immune cause of SPS. They manage symptoms by compensating for the GABA deficit, which means they need to be taken continuously.
Immune-Targeting Therapies
Because SPS is driven by the immune system, treatments that suppress or modulate immune function can reduce disease activity beyond what symptom medications achieve alone. The two most established approaches are intravenous immunoglobulin (IVIg) and plasma exchange.
IVIg delivers concentrated antibodies from healthy donors, which helps recalibrate the immune system. In a landmark randomized trial, 86% of patients showed improvement in walking ability, and about 79% improved overall. Multiple smaller studies have confirmed benefits for stiffness, spasms, and mobility, with response rates ranging from 33% to 100% depending on the study size and how improvement was measured. Long-term maintenance IVIg, given every few weeks, keeps symptoms controlled in roughly 30% to 40% of patients over time. This is not a cure, but for responders, it can be transformative.
Plasma exchange works by physically removing the harmful antibodies from the blood. Studies show improvement in stiffness and gait in 75% to 86% of patients treated this way. The benefit tends to be temporary, wearing off as the body produces new antibodies, so repeat sessions are often needed. For some patients who don’t respond to IVIg, plasma exchange provides an alternative path to relief.
Stronger immune-suppressing drugs like rituximab and tacrolimus are sometimes used for cases that don’t respond to other approaches, though evidence for these is more limited.
Stem Cell Transplant: The Closest Thing to a Cure
The most aggressive treatment studied for SPS is autologous hematopoietic stem cell transplant, a procedure that essentially reboots the immune system. A patient’s own stem cells are collected, high-dose chemotherapy destroys the existing immune system, and the stem cells are reinfused to rebuild it from scratch.
The results, while preliminary, are the most encouraging data available for long-term remission. In one trial of 23 SPS patients, 74% responded to the treatment, and 47% achieved sustained remissions lasting an average of 3.5 years. Some patients were able to stop all immune-suppressing medications and antispasmodic drugs entirely. In a separate UK group, four patients who received the transplant all reported improved mobility, and two who had been wheelchair-dependent regained the ability to walk independently. Two other patients with severe SPS were reported to return to their pre-illness level of functioning after the procedure.
These outcomes are remarkable, but context matters. The procedure carries significant risks, including infection and complications from the chemotherapy phase. Not everyone responds: 26% of patients in the larger trial showed no improvement at all. And some patients who initially improve eventually need to restart immune therapy. One case report described a patient whose stiffness began creeping back 17 months after transplant, requiring resumption of immune-suppressing medication. Stem cell transplant is currently available only through clinical trials or specialized centers, and it’s typically reserved for severe cases that haven’t responded to standard treatments.
How SPS Is Diagnosed
Diagnosis is notoriously difficult. The average time from symptom onset to diagnosis stretches years for many patients, partly because stiffness and spasms can mimic dozens of other conditions. A blood test measuring antibodies against the GAD65 enzyme is the single most useful diagnostic tool. Levels above 1,000 IU/mL on standard blood tests are highly specific for SPS, with 98.2% specificity. However, sensitivity is lower: only about half of people with confirmed SPS reach that threshold on blood testing. This means a negative or borderline antibody test doesn’t rule SPS out.
Doctors also look for continuous muscle activity on electromyography (EMG), assess spinal fluid for the presence of GAD antibodies and reduced GABA levels, and evaluate the clinical picture: progressive trunk stiffness, episodic spasms triggered by stimuli, and an exaggerated startle response. The condition is rarer than historically believed but more common than the old “one in a million” estimate. Recent population studies put the prevalence closer to 1 to 2 per 100,000 people, roughly 10 to 20 times higher than earlier figures suggested.
What Remission Looks Like
Because there is no cure, the realistic goal for most people with SPS is achieving the best possible symptom control while slowing disease progression. For some, this means a life that looks close to normal with consistent medication and periodic IVIg infusions. For others, it means reducing spasms enough to walk safely and manage daily tasks. Remission in SPS doesn’t mean the disease is gone. It means the immune attack is suppressed enough that the nervous system can function more normally, and maintaining that state requires ongoing treatment.
The outlook varies enormously from person to person. Factors that seem to matter include how early treatment begins, how well someone responds to immune therapy, and whether they develop complications like fixed joint deformities before adequate treatment is started. The disease progresses more slowly when treated early and aggressively, which makes timely diagnosis one of the most important factors in long-term quality of life.